

Special Issue

New Biologically Active Molecules for Combating Neurodegeneration and Viral Infection

Message from the Guest Editors

This Special Issue of *Molecules* is focused on recent approaches in developing innovative and “reincarnative” pharmaceutical agents for cure and prevention of viral infection and neurodegeneration. Notwithstanding big differences in these diseases, some chemical approaches in the design of novel, efficient drug-like agents could be quite similar. In conclusion, we welcome submissions that cover, but are not limited to, the following topics:

- Synthesis and study of novel agents for Alzheimer's disease;
- Synthesis and study of novel agents for Parkinson's disease;
- Synthesis and study of novel agents for ALS;
- Multi- and mono target approaches for development novel neuroprotectors and cognition enhancers;
- Old drugs for new approaches;
- Targeting coronavirus diseases by synthetic chemical entities and natural products;
- Antiviral properties of natural compounds and their synthetic derivatives;
- Target-oriented search for antiviral agents against emergent viruses;
- Development of surrogate systems to search for new antiviral agents

Guest Editors

Prof. Dr. Sergey O. Bachurin

Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia


Prof. Dr. Valery N. Charushin

1. Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, S. Kovalevskaya Str., 22, 620108 Ekaterinburg, Russia

2. Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute, Ural Federal University, Mira St. 19, 620002 Ekaterinburg, Russia

Deadline for manuscript submissions

closed (30 April 2022)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/90643

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of
Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore
- Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).